AF
LCTX icon

Allworth Financial’s Lineage Cell Therapeutics LCTX Stock Holding History

Allworth Financial’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$302 Buy
230
+208
+945% +$287 ﹤0.01% 4911
2026
Q1 		$35 Hold
22
– – ﹤0.01% 5096
2025
Q4 		$37 Sell
22
-9,983
-100% -$17.3K ﹤0.01% 4868
2025
Q3 		$16.9K Hold
10,005
– – ﹤0.01% 2808
2025
Q2 		$9.08K Hold
10,005
– – ﹤0.01% 2943
2025
Q1 		$4.99K Hold
10,005
– – ﹤0.01% 2762
2024
Q4 		$6.75K Sell
10,005
-4,750
-32% -$3.49K ﹤0.01% 2618
2024
Q3 		$13.4K Buy
14,755
+10,000
+210% +$9.27K ﹤0.01% 2129
2024
Q2 		$4.75K Hold
4,755
– – ﹤0.01% 2551
2024
Q1 		$7.04K Buy
4,755
+5
+0.1% +$6 ﹤0.01% 2258
2023
Q4 		$5.18K Hold
4,750
– – ﹤0.01% 2262
2023
Q3 		$5.61K Hold
4,750
– – ﹤0.01% 2057
2023
Q2 		$6.7K Hold
4,750
– – ﹤0.01% 1989
2023
Q1 		$7.13K Hold
4,750
– – ﹤0.01% 1909
2022
Q4 		$5.56K Hold
4,750
– – ﹤0.01% 1857
2022
Q3 		$5K Hold
4,750
– – ﹤0.01% 1884
2022
Q2 		$8K Hold
4,750
– – ﹤0.01% 1634
2022
Q1 		$7K Hold
4,750
– – ﹤0.01% 1567
2021
Q4 		$12K Hold
4,750
– – ﹤0.01% 1324
2021
Q3 		$12K Hold
4,750
– – ﹤0.01% 1227
2021
Q2 		$14K Buy
+4,750
New +$12.3K ﹤0.01% 945

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Allworth Financial's LCTX Position: Q2 2026 in Review

Allworth Financial increased its Lineage Cell Therapeutics (LCTX) stake by 945% in Q2 2026, buying an estimated $287 and bringing the position to 230 shares worth $302. The position accounts for ﹤0.01% of the portfolio, ranked #4911.

Allworth Financial first reported a position in LCTX in Q2 2021 and has held it in 21 quarters since. The position peaked at $16.9K in Q3 2025. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Allworth Financial held 230 shares of Lineage Cell Therapeutics worth $302 as of Q2 2026.
  • Allworth Financial bought 208 Lineage Cell Therapeutics shares in Q2 2026, an estimated $287.
  • Lineage Cell Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #4911 holding.
  • Allworth Financial first reported a position in Lineage Cell Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • Allworth Financial's Lineage Cell Therapeutics position peaked at $16.9K in Q3 2025.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.